Search Results - "Vritzali, Eleni"

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry by Walker, Ulrich A, Tilson, Hugh H, Hawkins, Philip N, Poll, Tom van der, Noviello, Stephanie, Levy, Jeremy, Vritzali, Eleni, Hoffman, Hal M, Kuemmerle-Deschner, Jasmin B

“…ObjectiveTo report the long-term safety and effectiveness of canakinumab, a fully human anti-interleukin 1β monoclonal antibody, in patients with…”
Get full text

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials by Lebwohl, Mark, Warren, Richard B, Sofen, Howard, Imafuku, Shinichi, Paul, Carle, Szepietowski, Jacek C, Spelman, Lynda, Passeron, Thierry, Vritzali, Eleni, Napoli, Andrew, Kisa, Renata M, Buck, Alex, Banerjee, Subhashis, Thaçi, Diamant, Blauvelt, Andrew

“…In the phase III POETYK PSO-1 and PSO-2 trials, deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, was well tolerated and efficacious…”
Get full text

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials by Ruperto, Nicolino, Brunner, Hermine I, Quartier, Pierre, Constantin, Tamàs, Wulffraat, Nico M, Horneff, Gerd, Kasapcopur, Ozgur, Schneider, Rayfel, Anton, Jordi, Barash, Judith, Berner, Reinhard, Corona, Fabrizia, Cuttica, Ruben, Fouillet-Desjonqueres, Marine, Fischbach, Michel, Foster, Helen E, Foell, Dirk, Radominski, Sebastião C, Ramanan, Athimalaipet V, Trauzeddel, Ralf, Unsal, Erbil, Levy, Jérémy, Vritzali, Eleni, Martini, Alberto, Lovell, Daniel J

“…To evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA). Patients (2-19 years)…”
Get more information

Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‐Label, Active‐Treatment Extension Study by Brunner, Hermine I., Quartier, Pierre, Alexeeva, Ekaterina, Constantin, Tamàs, Koné‐Paut, Isabelle, Marzan, Katherine, Schneider, Rayfel, Wulffraat, Nico M., Chasnyk, Vyacheslav, Tirosh, Irit, Kallinich, Tilmann, Kuemmerle‐Deschner, Jasmin, Wouters, Carine, Lauwerys, Bernard, Nikishina, Irina, Trachana, Maria, Vougiouka, Olga, Martini, Alberto, Lovell, Daniel J., Levy, Jeremy, Vritzali, Eleni, Ruperto, Nicolino

“…Objective To evaluate the long‐term efficacy and safety of canakinumab and explore prediction of response in patients with systemic juvenile idiopathic…”
Get full text

Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study by Jaeger, Veronika K, Hoffman, Hal M, van der Poll, Tom, Tilson, Hugh, Seibert, Julia, Speziale, Antonio, Junge, Guido, Franke, Kristina, Vritzali, Eleni, Hawkins, Philip N, Kuemmerle-Deschner, Jasmin, Walker, Ulrich A

“…Pneumococcal, tetanus and influenza vaccinations are recommended for patients with cryopyrin-associated periodic syndromes (CAPS) when treated with…”
Get full text

Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece by Athanasakis, Kostas, Tarantilis, Filippos, Tsalapati, Konstantina, Konstantopoulou, Thomais, Vritzali, Eleni, Kyriopoulos, John

“…The study aims to evaluate the cost-effectiveness of adding tocilizumab (TCZ) first line to a treatment sequence for patients with active rheumatoid arthritis…”
Get full text

Deucravacitinib Long-Term Efficacy in Week 16 Placebo Crossovers: 3-year Results from the POETYK PSO Program by Lebwohl, Mark, Warren, Richard B., Imafuku, Shinichi, Bagel, Jerry, Armstrong, April W., Passeron, Thierry, Banerjee, Subhashis, Kisa, Renata M., Vritzali, Eleni, Colombo, Matthew J., Scharnitz, Thomas, Hoyt, Kim, Thaçi, Diamant, Blauvelt, Andrew

“…Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with…”
Get full text

Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials by Armstrong, April W., Lebwohl, Mark, Warren, Richard B., Sofen, Howard, Imafuku, Shinichi, Ohtsuki, Mamitaro, Spelman, Lynda, Passeron, Thierry, Papp, Kim A., Kisa, Renata M., Berger, Victoria, Vritzali, Eleni, Hoyt, Kim, Colombo, Matthew J., Banerjee, Subhashis, Strober, Bruce, Thaçi, Diamant, Blauvelt, Andrew

“…Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with…”
Get full text

Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials by Armstrong, April W., Lebwohl, Mark, Warren, Richard B., Sofen, Howard, Imafuku, Shinichi, Ohtsuki, Mamitaro, Spelman, Lynda, Passeron, Thierry, Papp, Kim A., Kisa, Renata M., Berger, Victoria, Vritzali, Eleni, Hoyt, Kim, Colombo, Matthew J., Banerjee, Subhashis, Strober, Bruce, Thaçi, Diamant, Blauvelt, Andrew

“…Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for the treatment of…”
Get full text

Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials by Armstrong, April W., Lebwohl, Mark, Warren, Richard B., Sofen, Howard, Morita, Akimichi, Imafuku, Shinichi, Ohtsuki, Mamitaro, Spelman, Lynda, Passeron, Thierry, Papp, Kim A., Colombo, Matthew J., Vaile, John, Vritzali, Eleni, Hoyt, Kim, Daamen, Carolin, Banerjee, Subhashis, Strober, Bruce, Thaçi, Diamant, Blauvelt, Andrew

“…Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in multiple countries for treatment of adults with moderate to severe…”
Get full text

Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study by Vassilopoulos, Dimitrios, Delicha, Evie M, Settas, Loukas, Andrianakos, Alexandros, Aslanidis, Spyros, Boura, Panagiota, Katsounaros, Marios, Athanassiou, Panagiotis, Tempos, Konstantinos, Skarantavos, Grigorios, Antoniadis, Christodoulos, Papazoglou, Sotirios, Sakkas, Lazaros, Galanopoulou, Vassiliki, Skopouli, Fotini, Boki, Kyriaki, Daoussis, Dimitrios, Vritzali, Eleni, Sfikakis, Petros P

“…To evaluate the long-term safety of rituximab (RTX) in rheumatoid arthritis (RA) patients in daily clinical practice. This was a multicentre (17 Greek…”
Get full text

Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials by Armstrong, April W., Lebwohl, Mark, Warren, Richard B., Sofen, Howard, Morita, Akimchi, Imafuku, Shinichi, Ohtsuki, Mamitaro, Spelman, Lynda, Passeron, Thierry, Papp, Kim A., Colombo, Matthew J., Vaile, John, Vritzali, Eleni, Hoyt, Kim, Daamen, Carolin, Banerjee, Subhashis, Strober, Bruce, Thaçi, Diamant, Blauvelt, Andrew

“…Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with…”
Get full text

Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials by Sofen, Howard, Strober, Bruce, Imafuku, Shinichi, Paul, Carle, Gooderham, Melinda, Spelman, Lynda, Seo, Seong Jun, Passeron, Thierry, Kisa, Renata M., Berger, Victoria, Vritzali, Eleni, Hoyt, Kim, Colombo, Matthew J., Banerjee, Subhashis, Augustin, Matthias, Stein Gold, Linda, Alexis, Andrew, Thaçi, Diamant, Blauvelt, Andrew, Lebwohl, Mark

“…Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor for moderate-to-severe plaque psoriasis, was superior to placebo and…”
Get full text